Metabolic & Weight Management

Maridebart cafraglutide

Also known as MariTide · AMG 133

Clinically studiedSubcutaneous injectionInvestigational; not approved by the FDA (in phase 3 clinical development as of 2026). As an experimental biologic conjugate not on the FDA's compounding bulk-drug substance lists, it is not a lawfully compounded 503A/503B product. GLP-1 receptor agonists are not specifically named on the WADA Prohibited List, but athletes remain subject to general anti-doping rules and should verify current status with their governing body.

Maridebart cafraglutide (MariTide, AMG 133) is an investigational injectable being developed by Amgen for obesity and related metabolic conditions. It is a bispecific molecule combining a monoclonal antibody that antagonizes the glucose-dependent insulinotropic polypeptide receptor (GIPR) conjugated to two peptide agonists of the glucagon-like peptide-1 receptor (GLP-1R), a dual mechanism intended to act on appetite and energy regulation. Its long half-life supports an extended (reported as monthly) dosing interval, distinguishing it from weekly GLP-1 therapies. Evidence includes a published phase 1 study and a randomized, placebo-controlled phase 2 trial in adults with obesity or overweight (reported in the New England Journal of Medicine in 2025), with a phase 3 MARITIME program underway. As of 2026 it remains investigational and has not received regulatory approval.

Studied / used for

Investigated for chronic weight management in adults with obesity or overweight
Studied in people with obesity or overweight and type 2 diabetes
Investigated for cardiometabolic parameters associated with obesity

Commonly reported side effects

Nausea (commonly reported, often around the first dose)
Vomiting (commonly reported, generally transient)
Constipation
Other gastrointestinal complaints such as diarrhea reported in trials

Clinically studied. Supported by human clinical trials. This reflects the strength of the research base, not effectiveness or a recommendation.

Not medical advice.

This is an educational reference. Peptalk does not recommend, prescribe, endorse, or rate any compound, and provides no dosing information. Do not start, stop, or change any peptide, hormone, supplement, or therapy based on this page. All clinical decisions must be made with your licensed healthcare provider.

← Back to all compounds